.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Maintaining AS-3 blood transfusion safety is a major priority for pediatric cardiac surgeons and anesthesiologists managing complex cases. Traditionally, clinicians used red blood cells stored in anticoagulant-citrate-phosphate-dextrose (CPD) for large-volume transfusions (LVT). Many centers hesitated to adopt additive solutions like AS-3 for infants due to potential metabolic risks. However, recent evidence suggests that these concerns may not translate into adverse clinical outcomes. Specifically, a retrospective review examined the impact of transitioning from CPD to AS-3 products in high-risk procedures.
The study analyzed 89 pediatric patients undergoing Norwood procedures or heart transplants. Researchers monitored laboratory values before surgery, immediately afterward, and one day later. Notably, patients receiving AS-3 products showed significantly higher levels of sodium, glucose, and phosphorus immediately post-surgery. Furthermore, lactate levels varied depending on the procedure. Infants undergoing the Norwood procedure in the AS-3 group had higher lactate, likely due to their younger age. Conversely, heart transplant recipients in the AS-3 group exhibited lower lactate levels immediately and on the first postoperative day.
Crucially, these metabolic shifts were transient. All laboratory abnormalities associated with the additive solution fully resolved within 24 hours. Consequently, the study found no significant differences in mortality between the CPD and AS-3 groups. Additionally, the total length of stay (LOS) and intensive care unit (ICU) duration remained consistent across both cohorts. Therefore, the results support the safe use of AS-3 stored products even in the context of large-volume pediatric transfusions. This transition potentially simplifies blood bank inventory management without compromising patient care.
In summary, while AS-3 solutions introduce temporary electrolyte and glucose changes, they do not appear to impact long-term recovery or survival. Surgeons and anesthesiologists can feel more confident in the safety profile of these modern blood storage methods. This analysis provides essential data for hospitals considering a switch from traditional anticoagulant storage to more versatile additive solutions for neonatal and pediatric cardiac care.
No, the study demonstrated that mortality rates were similar between the CPD and AS-3 groups, indicating that the choice of storage solution does not impact survival outcomes.
Patients may experience transient increases in sodium, glucose, and phosphorus immediately after a large-volume transfusion. However, these levels typically return to normal within 24 hours.
The study suggests that AS-3 is a safe alternative to CPD. While it causes minor laboratory fluctuations, it offers similar clinical safety in terms of hospital stay and mortality.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Clinicians should use their professional judgment and consider individual patient factors. Refer to the latest local and national guidelines for clinical practice.
References
Saifee NH et al. Red blood cells stored in anticoagulant versus additive solution for large volume transfusions in pediatric patients undergoing cardiopulmonary bypass. Transfusion. 2026 Jun 18. doi: 10.1111/trf.70297. PMID: 42313418.
Strauss RG et al. AS-1 red cells for neonatal transfusions: A randomized trial assessing donor exposure and safety. Transfusion 1996;36:873-8.
New HV et al. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol 2016;175:784-828.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study compared CPD and AS-3 stored red blood cells for large-volume transfusions in pediatric cardiac surgery. While AS-3 caused transient metabolic changes in sodium and glucose, these resolved within 24 hours and did not affect mortality or length of stay, confirming the safety of AS-3 products.
4 months ago
Depemokimab offers twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, significantly cutting exacerbations and hospital admissions.
3 days back
A novel copper metal-organic framework hydrogel remodels the uterine microenvironment to stimulate robust endometrial regeneration, reduce intrauterine fibrosis, and restore reproductive fertility, offering a groundbreaking strategy for managing refractory endometrial damage and Asherman syndrome.
4 days back
New research reveals that non-ablative radiotherapy suppresses ventricular tachycardia by increasing conduction velocity via NaV1.5 upregulation and action potential prolongation. However, sustained sodium current elevation and depressed calcium handling highlight the need for careful clinical translation.
6 days back
A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
4 days back
A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
4 days back
